Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704.

Reyngold M, Winter KA, Regine WF, Abrams RA, Safran H, Hoffman JP, Mowat RB, Hayes JP, Kessel IL, DiPetrillo T, Narayan S, Chen Y, Ben-Josef E, Delouya G, Suh JH, Meyer J, Haddock MG, Feldman M, Gaur R, Yost K, Peterson RA, Sherr DL, Moughan J, Crane CH.

Oncologist. 2020 Mar;25(3):e477-e483. doi: 10.1634/theoncologist.2019-0562. Epub 2019 Dec 16.

2.

Prometastatic Secretome Trafficking via Exosomes Initiates Pancreatic Cancer Pulmonary Metastasis.

Ogawa K, Lin Q, Li L, Bai X, Chen X, Chen H, Kong R, Wang Y, Zhu H, He F, Xu Q, Liu L, Li M, Zhang S, Nagaoka K, Carlson R, Safran H, Charpentier K, Sun B, Wands J, Dong X.

Cancer Lett. 2020 Mar 4. pii: S0304-3835(20)30108-7. doi: 10.1016/j.canlet.2020.02.039. [Epub ahead of print]

PMID:
32145343
3.

Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial.

Abrams RA, Winter KA, Safran H, Goodman KA, Regine WF, Berger AC, Gillin MT, Philip PA, Lowy AM, Wu A, DiPetrillo TA, Corn BW, Seaward SA, Haddock MG, Song S, Jiang Y, Fisher BJ, Katz AW, Mehta S, Willett CG, Crane CH.

Am J Clin Oncol. 2020 Mar;43(3):173-179. doi: 10.1097/COC.0000000000000633.

PMID:
31985516
4.

Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.

Ogawa K, Lin Q, Li L, Bai X, Chen X, Chen H, Kong R, Wang Y, Zhu H, He F, Xu Q, Liu L, Li M, Zhang S, Nagaoka K, Carlson R, Safran H, Charpentier K, Sun B, Wands J, Dong X.

J Hematol Oncol. 2019 Dec 30;12(1):144. doi: 10.1186/s13045-019-0837-z.

5.

Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704.

Reyngold M, Winter KA, Regine WF, Abrams RA, Safran H, Hoffman JP, Mowat RB, Hayes JP, Kessel IL, DiPetrillo T, Narayan S, Chen Y, Ben-Josef E, Delouya G, Suh JH, Meyer J, Haddock MG, Feldman M, Gaur R, Yost K, Peterson RA, Sherr DL, Moughan J, Crane CH.

Oncologist. 2019 Dec 16. pii: theoncologist.2019-0562. doi: 10.1634/theoncologist.2019-0562. [Epub ahead of print]

6.

Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing Radiation.

Kinsella T, Safran H, Wiersma S, DiPetrillo T, Schumacher A, Rosati K, Vatkevich J, Anderson LW, Hill KD, Kunos C, Collins JM.

Clin Cancer Res. 2019 Oct 15;25(20):6035-6043. doi: 10.1158/1078-0432.CCR-19-0862. Epub 2019 Jul 23.

PMID:
31337643
7.

ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma.

Marks EI, Pamarthy S, Dizon D, Birnbaum A, Yakirevich E, Safran H, Carneiro BA.

Oncotarget. 2019 Jan 4;10(2):245-251. doi: 10.18632/oncotarget.26521. eCollection 2019 Jan 4.

8.

Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.

Chung HC, Arkenau HT, Lee J, Rha SY, Oh DY, Wyrwicz L, Kang YK, Lee KW, Infante JR, Lee SS, Kemeny M, Keilholz U, Melichar B, Mita A, Plummer R, Smith D, Gelb AB, Xiong H, Hong J, Chand V, Safran H.

J Immunother Cancer. 2019 Feb 4;7(1):30. doi: 10.1186/s40425-019-0508-1.

9.

Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704.

Regine WF, Winter K, Abrams RA, Safran H, Kessel IL, Chen Y, Fugazzi JA, Donnelly ED, DiPetrillo TA, Narayan S, Plastaras JP, Gaur R, Delouya G, Suh JH, Meyer JE, Haddock MG, Didolkar MS, Padula GDA, Johnson D, Hoffman JP, Crane CH.

Adv Radiat Oncol. 2018 Feb 9;3(2):154-162. doi: 10.1016/j.adro.2018.01.003. eCollection 2018 Apr-Jun.

10.

Tolerability of ADXS11-001 Lm-LLO Listeria-Based Immunotherapy With Mitomycin, Fluorouracil, and Radiation for Anal Cancer.

Safran H, Leonard KL, Perez K, Vrees M, Klipfel A, Schechter S, Oldenburg N, Roth L, Shah N, Rosati K, Rajdev L, Mantripragada K, Sheng IY, Barth P, DiPetrillo TA.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1175-1178. doi: 10.1016/j.ijrobp.2018.01.004. Epub 2018 Jan 31.

PMID:
29722659
11.

Prechemotherapy Education: Reducing Patient Anxiety Through Nurse-Led Teaching Sessions
.

Apor E, Connell NT, Faricy-Anderson K, Barth P, Youssef R, Fenton M, Sikov WM, Thomas A, Rosati K, Schumacher A, Lombardo A, Korber S, Khurshid H, Safran H, Mega A.

Clin J Oncol Nurs. 2018 Feb 1;22(1):76-82. doi: 10.1188/18.CJON.76-82.

PMID:
29350695
12.

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer.

Grothey A, Strosberg JR, Renfro LA, Hurwitz HI, Marshall JL, Safran H, Guarino MJ, Kim GP, Hecht JR, Weil SC, Heyburn J, Wang W, Schweizer C, O'Shannessy DJ, Diaz LA Jr.

Clin Cancer Res. 2018 Jan 15;24(2):316-325. doi: 10.1158/1078-0432.CCR-17-1558. Epub 2017 Oct 30.

13.

Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study.

Winer ES, Safran H, Karaszewska B, Bauer S, Khan D, Doerfel S, Burgess P, Kalambakas S, Mostafa Kamel Y, Forget F.

Int J Hematol. 2017 Dec;106(6):765-776. doi: 10.1007/s12185-017-2319-9. Epub 2017 Sep 1.

PMID:
28864871
14.

Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11-001.

Miles B, Safran HP, Monk BJ.

Gynecol Oncol Res Pract. 2017 Jul 14;4:10. doi: 10.1186/s40661-017-0047-8. eCollection 2017. Review.

15.

Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer.

Tabernero J, Ohtsu A, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Ajani JA, Tomasek J, Safran H, Chandrawansa K, Hsu Y, Heathman M, Khan A, Ni L, Melemed AS, Gao L, Ferry D, Fuchs CS.

Mol Cancer Ther. 2017 Oct;16(10):2215-2222. doi: 10.1158/1535-7163.MCT-16-0895. Epub 2017 Jul 17.

16.

Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial.

Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic L, Konski A, Chakravarthy AB, Anker CJ, Thakrar H, Horiba N, Dubey A, Greenberger JS, Raben A, Giguere J, Roof K, Videtic G, Pollock J, Safran H, Crane CH.

JAMA Oncol. 2017 Nov 1;3(11):1520-1528. doi: 10.1001/jamaoncol.2017.1598. Erratum in: JAMA Oncol. 2017 Nov 1;3(11):1589.

17.

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data.

Fuchs CS, Muro K, Tomasek J, Van Cutsem E, Cho JY, Oh SC, Safran H, Bodoky G, Chau I, Shimada Y, Al-Batran SE, Passalacqua R, Ohtsu A, Emig M, Ferry D, Chandrawansa K, Hsu Y, Sashegyi A, Liepa AM, Wilke H.

J Gastric Cancer. 2017 Jun;17(2):132-144. doi: 10.5230/jgc.2017.17.e16. Epub 2017 Jun 16.

18.

Prognostic significance of IgG4+ plasma cell infiltrates following neoadjuvant chemoradiation therapy for esophageal adenocarcinoma.

Yakirevich E, Lu S, Allen D, Mangray S, Fanion JR, Lombardo KA, Safran H, Resnick MB.

Hum Pathol. 2017 Aug;66:126-135. doi: 10.1016/j.humpath.2017.06.009. Epub 2017 Jun 28.

PMID:
28666927
19.

Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy.

Miles BA, Monk BJ, Safran HP.

Gynecol Oncol Res Pract. 2017 Jun 2;4:9. doi: 10.1186/s40661-017-0046-9. eCollection 2017. Review.

20.

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.

Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe TE, Srdanov M, Gelb AB, Schlichting M, Chin K, Gulley JL.

J Clin Oncol. 2017 Jul 1;35(19):2117-2124. doi: 10.1200/JCO.2016.71.6795. Epub 2017 Apr 4.

21.

Informed consent in oncology clinical trials: A Brown University Oncology Research Group prospective cross-sectional pilot study.

Schumacher A, Sikov WM, Quesenberry MI, Safran H, Khurshid H, Mitchell KM, Olszewski AJ.

PLoS One. 2017 Feb 24;12(2):e0172957. doi: 10.1371/journal.pone.0172957. eCollection 2017.

22.

Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Dose Escalation Study.

Hepel JT, Leonard KL, Safran H, Ng T, Taber A, Khurshid H, Birnbaum A; Brown University Oncology Research Group, Wazer DE, DiPetrillo T.

Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1021-1027. doi: 10.1016/j.ijrobp.2016.08.032. Epub 2016 Aug 31.

PMID:
27745983
23.

Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab.

Fuchs CS, Tabernero J, Tomášek J, Chau I, Melichar B, Safran H, Tehfe MA, Filip D, Topuzov E, Schlittler L, Udrea AA, Campbell W, Brincat S, Emig M, Melemed SA, Hozak RR, Ferry D, Caldwell CW, Ajani JA.

Br J Cancer. 2016 Oct 11;115(8):974-982. doi: 10.1038/bjc.2016.293. Epub 2016 Sep 13.

24.

Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.

Olszanski AJ, Smith DC, Camacho LH, Thompson J, Ramalingam SS, Harvey RD, Campos L, Ferry D, Tang S, Gao L, Safran H.

Oncologist. 2016 Apr;21(4):402-3. doi: 10.1634/theoncologist.2015-0467. Epub 2016 Mar 16.

25.

Optimizing initial chemotherapy for metastatic pancreatic cancer.

Mantripragada KC, Safran H.

Future Oncol. 2016 May;12(9):1125-33. doi: 10.2217/fon-2015-0006. Epub 2016 Mar 4.

PMID:
26939741
26.

Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.

Yakirevich E, Resnick MB, Mangray S, Wheeler M, Jackson CL, Lombardo KA, Lee J, Kim KM, Gill AJ, Wang K, Gowen K, Sun J, Miller VA, Stephens PJ, Ali SM, Ross JS, Safran H.

Clin Cancer Res. 2016 Aug 1;22(15):3831-40. doi: 10.1158/1078-0432.CCR-15-3000. Epub 2016 Mar 1.

27.

Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program.

Mantripragada KC, Olszewski AJ, Schumacher A, Perez K, Birnbaum A, Reagan JL, Mega A, Khurshid H, Bartley C, Lombardo A, Rossiter R, Papa A, Bakalarski P, Safran H.

J Oncol Pract. 2016 Apr;12(4):e396-404. doi: 10.1200/JOP.2015.008433. Epub 2016 Feb 23.

PMID:
26907448
28.

RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704.

Li D, Moughan J, Crane C, Hoffman JP, Regine WF, Abrams RA, Safran H, Liu C, Chang P, Freedman GM, Winter KA, Guha C, Abbruzzese JL.

Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):554-60. doi: 10.1016/j.ijrobp.2015.10.062. Epub 2015 Nov 5.

29.

PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244.

Elinzano H, Glantz M, Mrugala M, Kesari S, Piccioni DE, Kim L, Pan E, Yunus S, Coyle T, Timothy K, Evans D, Mantripragada K, Boxerman J, DiPetrillo T, Donahue JE, Hebda N, Mitchell KM, Rosati KL, Safran H.

Am J Clin Oncol. 2018 Feb;41(2):159-162. doi: 10.1097/COC.0000000000000247.

PMID:
26658237
30.

Nonengraftment donor lymphocyte infusions for refractory acute myeloid leukemia.

Reagan JL, Fast LD, Nevola M, Mantripragada K, Mulder A, Claas FH, Rosati K, Schumacher A, Safran H, Young CT, Quesenberry MI, Winer ES, Butera JN, Quesenberry PJ.

Blood Cancer J. 2015 Dec 4;5:e371. doi: 10.1038/bcj.2015.100. No abstract available.

31.

FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer: A Brown University Oncology Research Group Phase I Study.

Safran H, Charpentier KP, Perez K, Mantripragada K, Miner T, DiPetrillo T, Kuritzky B, Apor E, Bishop K, Luppe D, Mitchell K, Rosati K.

Am J Clin Oncol. 2016 Dec;39(6):619-622.

PMID:
26523444
32.

Updates in Tumor Profiling in Gastrointestinal Cancers.

Perez K, Safran HP.

R I Med J (2013). 2015 Oct 1;98(10):21-4.

PMID:
26422541
33.
34.

A Novel SDHA-deficient Renal Cell Carcinoma Revealed by Comprehensive Genomic Profiling.

Yakirevich E, Ali SM, Mega A, McMahon C, Brodsky AS, Ross JS, Allen J, Elvin JA, Safran H, Resnick MB.

Am J Surg Pathol. 2015 Jun;39(6):858-63. doi: 10.1097/PAS.0000000000000403.

PMID:
25724004
35.

Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma.

Tomimaru Y, Mishra S, Safran H, Charpentier KP, Martin W, De Groot AS, Gregory SH, Wands JR.

Vaccine. 2015 Mar 3;33(10):1256-66. doi: 10.1016/j.vaccine.2015.01.037. Epub 2015 Jan 25.

36.

Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.

Boxerman JL, Ellingson BM, Jeyapalan S, Elinzano H, Harris RJ, Rogg JM, Pope WB, Safran H.

Am J Clin Oncol. 2017 Jun;40(3):228-234. doi: 10.1097/COC.0000000000000156.

PMID:
25436828
37.

Complete Neoadjuvant Treatment for Rectal Cancer: The Brown University Oncology Group CONTRE Study.

Perez K, Safran H, Sikov W, Vrees M, Klipfel A, Shah N, Schechter S, Oldenburg N, Pricolo V, Rosati K, Dipetrillo T.

Am J Clin Oncol. 2017 Jun;40(3):283-287. doi: 10.1097/COC.0000000000000149.

PMID:
25374145
38.

Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study.

Winer ES, Safran H, Karaszewska B, Richards DA, Hartner L, Forget F, Ramlau R, Kumar K, Mayer B, Johnson BM, Messam CA, Mostafa Kamel Y.

Cancer Med. 2015 Jan;4(1):16-26. doi: 10.1002/cam4.326. Epub 2014 Aug 28.

39.

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J; REGARD Trial Investigators.

Lancet. 2014 Jan 4;383(9911):31-39. doi: 10.1016/S0140-6736(13)61719-5. Epub 2013 Oct 3.

PMID:
24094768
40.

Cellular immunotherapy for refractory hematological malignancies.

Reagan JL, Fast LD, Safran H, Nevola M, Winer ES, Castillo JJ, Butera JN, Quesenberry MI, Young CT, Quesenberry PJ.

J Transl Med. 2013 Jun 19;11:150. doi: 10.1186/1479-5876-11-150.

41.

Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.

Safran H, Charpentier KP, Kaubisch A, Mantripragada K, Dubel G, Perez K, Faricy-Anderson K, Miner T, Eng Y, Victor J, Plette A, Espat J, Bakalarski P, Wingate P, Berz D, Luppe D, Martel D, Rosati K, Aparo S.

Am J Clin Oncol. 2015 Feb;38(1):1-4. doi: 10.1097/COC.0b013e3182868c66.

PMID:
23648434
42.

Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology.

Perez K, Walsh R, Brilliant K, Noble L, Yakirevich E, Breese V, Jackson C, Chatterjee D, Pricolo V, Roth L, Shah N, Cataldo T, Safran H, Hixson D, Quesenberry P.

Exp Mol Pathol. 2013 Aug;95(1):74-82. doi: 10.1016/j.yexmp.2013.01.004. Epub 2013 Mar 22.

43.

Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study.

Jeyapalan S, Boxerman J, Donahue J, Goldman M, Kinsella T, Dipetrillo T, Evans D, Elinzano H, Constantinou M, Stopa E, Puthawala Y, Cielo D, Santaniello A, Oyelese A, Mantripragada K, Rosati K, Isdale D, Safran H; Brown University Oncology Group Study.

Am J Clin Oncol. 2014 Oct;37(5):444-9. doi: 10.1097/COC.0b013e31827de92b.

PMID:
23388562
44.

Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a survival analysis of a Brown University Oncology Group phase II study.

Birnbaum A, Dipetrillo T, Rathore R, Merriam P, Wanebo H, Thomas A, Puthawala Y, Joyce D, Luppe D, Khurshid H, Follett N, Sio TT, Safran H.

Am J Clin Oncol. 2014 Apr;37(2):162-6. doi: 10.1097/COC.0b013e31826e06e0.

PMID:
23275269
45.

Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.

Hardacre JM, Mulcahy M, Small W, Talamonti M, Obel J, Krishnamurthi S, Rocha-Lima CS, Safran H, Lenz HJ, Chiorean EG.

J Gastrointest Surg. 2013 Jan;17(1):94-100; discussion p. 100-1. doi: 10.1007/s11605-012-2064-6. Epub 2012 Nov 15.

PMID:
23229886
46.

RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.

Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, Haddock MG, Rotman M, Parikh PJ, Safran H, Willett CG.

Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):27-33. doi: 10.1016/j.ijrobp.2012.09.023. Epub 2012 Nov 12.

47.

Dosimetric Feasibility of Dose Escalation Using SBRT Boost for Stage III Non-Small Cell Lung Cancer.

Hepel JT, Peter J, Hiatt JR, Patel S, Osibanjo O, Safran H, Curran B, Dipetrillo T.

Front Oncol. 2012 Sep 26;2:124. doi: 10.3389/fonc.2012.00124. eCollection 2012.

48.

Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer.

Rich TA, Winter K, Safran H, Hoffman JP, Erickson B, Anne PR, Myerson RJ, Cline-Burkhardt VJ, Perez K, Willett C.

Onco Targets Ther. 2012;5:161-70. doi: 10.2147/OTT.S33560. Epub 2012 Aug 23.

49.

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.

Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson JJ Jr, Rocha-Lima CM, Safran H, Chan D, Kocs DM, Galimi F, McGreivy J, Bray SL, Hei Y, Feigal EG, Loh E, Fuchs CS.

Ann Oncol. 2012 Nov;23(11):2834-42. doi: 10.1093/annonc/mds142. Epub 2012 Jun 13.

50.

Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trial.

Berger AC, Winter K, Hoffman JP, Regine WF, Abrams RA, Safran H, Freedman GM, Benson AB 3rd, Macdonald J, Willett CG.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):e291-7. doi: 10.1016/j.ijrobp.2012.04.035. Epub 2012 Jun 9.

PMID:
22682806

Supplemental Content

Loading ...
Support Center